Outcome differences between PD-1/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases

INTRODUCTION: Without the clear immunophenotyping of brain metastases (BrMs), the optimal treatment strategy based on PD-1/PD-L1 inhibitor for patients with non-small-cell lung cancer (NSCLC) and BrMs remains unknown. METHODS: 308 patients with NSCLC received PD-1/PD-L1 inhibitor-based monotherapy o...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Haowei, Liu, Fangfang, Chen, Xiaoxia, Zhao, Chao, Li, Xuefei, Zhou, Caicun, Hu, Jie, Chu, Qian, Jiang, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288673/
https://www.ncbi.nlm.nih.gov/pubmed/37353805
http://dx.doi.org/10.1186/s40164-023-00412-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288673/
https://www.ncbi.nlm.nih.gov/pubmed/37353805
http://dx.doi.org/10.1186/s40164-023-00412-3

Ejemplares similares